CN109957528A - 可调节免疫耐受发育延缓变应性进程的菌株 - Google Patents

可调节免疫耐受发育延缓变应性进程的菌株 Download PDF

Info

Publication number
CN109957528A
CN109957528A CN201711430811.5A CN201711430811A CN109957528A CN 109957528 A CN109957528 A CN 109957528A CN 201711430811 A CN201711430811 A CN 201711430811A CN 109957528 A CN109957528 A CN 109957528A
Authority
CN
China
Prior art keywords
group
allergia
flora
immunity
adjusting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201711430811.5A
Other languages
English (en)
Inventor
文姝
唐立
潘浩宇
张瑾
刘银辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dalian Medical University
Original Assignee
Dalian Medical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dalian Medical University filed Critical Dalian Medical University
Priority to CN201711430811.5A priority Critical patent/CN109957528A/zh
Publication of CN109957528A publication Critical patent/CN109957528A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

本发明公开一种从正常人鼻腔中分离出具有调节免疫耐受发育的益生菌株—表皮葡萄球菌，可通过调节皮肤菌群调节免疫耐受发育，进而延缓变应性进程。同时可与鼻腔菌群调节、肠道菌群调节共同作用，有效增强延缓变应性进程的效果，其中肠道菌群调节可通过系统免疫调节呼吸道局部免疫，鼻腔菌群调节可直接调节呼吸道局部免疫。

Description

可调节免疫耐受发育延缓变应性进程的菌株
技术领域
本发明涉及一种菌株，尤其是一种可调节免疫耐受发育延缓变应性进程的菌株。
背景技术
变应性进程是指从湿疹、皮炎发展到过敏性鼻炎以及过敏性哮喘的自然演进过程，而这些疾病都是超敏反应造成的I型变态反应，主要特征是免疫球蛋白IgE升高，免疫耐受是变应性进程的主要原因。现阶段针对于过敏性鼻炎和过敏性哮喘的药物主要是β受体激动剂和糖皮质激素喷雾等疗法，可以有效缓解和控制疾病症状，但是具有副作用，对治疗后的生活质量有影响，而且不能根治。近年来也出现了以调节免疫耐受功能为目标的免疫疗法，对过敏性鼻炎和过敏性哮喘的治疗有效果，但是局部和全身也会出现不良反应，安全性需要进一步评价。也有用益生菌制剂对湿疹、变应性鼻炎、哮喘等疾病的防治研究报道，如口服益生菌包括鼠李糖乳杆菌LGG、双歧杆菌等，结果是针对于湿疹的治疗取得了良好的作用，但对于过敏性鼻炎和过敏性哮喘的治疗基本无效。
婴幼儿期是免疫耐受发育时期，免疫耐受发育受到遗传基因、表观遗传、环境因素的共同影响，其中微生物的刺激作用特别是婴幼儿时期菌群的正常定植十分重要，而生命早期免疫耐受的发育对后期生命过程避免出现变应性进程具有重要作用。但是，迄今为止并没有关于可调节免疫耐受发育、延缓变应性进程菌株的相关报道。
发明内容
本发明是为了解决现有技术所存在的上述技术问题，提供一种可调节免疫耐受发育延缓变应性进程的菌株。
本发明的技术解决方案是一种可调节免疫耐受发育延缓变应性进程的菌株，其特征在于：所述菌株为表皮葡萄球菌。
本发明首次从正常人鼻腔中分离出具有调节免疫耐受发育的益生菌株—表皮葡萄球菌，可通过调节皮肤菌群调节免疫耐受发育，进而延缓变应性进程。同时可与鼻腔菌群调节、肠道菌群调节共同作用，有效增强延缓变应性进程的效果，其中肠道菌群调节可通过系统免疫调节呼吸道局部免疫，鼻腔菌群调节可直接调节呼吸道局部免疫。
附图说明
图1是本发明实施例各实验组抓鼻次数统计示意图。
图2是本发明实施例各实验组血细胞计数示意图。
图3是本发明实施例各实验组肺灌洗液及鼻腔灌洗液中白细胞计数示意图。
图4是本发明实施例各实验组鼻腔灌洗液、肺灌洗液及血清中IgE含量示意图。
图5是本发明实施例各实验组鼻腔灌洗液、肺灌洗液及血清中IL-10、IL-6含量示意图。
具体实施方式
从正常人鼻腔中分离出具有调节免疫耐受发育的益生菌株—表皮葡萄球菌。
实验：
对离乳期幼鼠进行过敏性进程造模（M组），处理组用本发明实施例所得到的表皮葡萄球菌（1x103）进行皮肤菌群调节（Me组）；皮肤、鼻腔、肠道联合菌群调节（MePCE组），其中皮肤采用表皮葡萄球菌（1x103）涂抹方法进行皮肤菌群调节、鼻腔采用表皮葡萄球菌菌（1x105）滴鼻方法进行菌群调节、肠道采用副干酪乳杆菌（1x109）及4%纤维素灌胃方法进行菌群调节；正常对照组（C组）不做治疗处理。皮肤处理27天，肠道及呼吸道处理18天后，对疾病严重程度、特异性OVA-IgE水平、与免疫耐受相关的免疫因子变化进行检测。
结果如下，
1. 各实验组抓鼻次数统计如图1所示：Me组、MePCE组抓鼻次数与M组比显著下降（p<0.05,p<0.001）。
2. 各实验组血细胞计数如图2所示：外周血中的白细胞数Me组、MePCE组与M组比显著下降（p<0.01），嗜酸性粒细胞数量Me组、MePCE组与M组比显著下降（p<0.01）。
3. 各实验组肺灌洗液及鼻腔灌洗液中白细胞计数如图3所示：肺灌洗液中白细胞数量，与M组相比Me组有下降趋势，MePCE组显著下降（p<0.01）。鼻腔灌洗液中白细胞数量，与M组相比Me组、MePCE组显著下降（p<0.01,p<0.001）。
从图1、图2、图3可以看出，本发明实施例表皮葡萄球菌的调节可以降低疾病的严重程度，联合菌群调节方式效果更好。
4. 各实验组鼻腔灌洗液、肺灌洗液及血清中IgE含量如图4所示：鼻腔灌洗液中，与M组比，Me组、MePCE组显著下降（p<0.05,p<0.001）；肺灌洗液中，与M组比，Me组、MePCE组显著下降（p<0.001,p<0.001）；血清中，与M组比，Me组、MePCE组显著下降（p<0.001,p<0.001）。
从图4可以看出，本发明实施例表皮葡萄球菌的调节可以有效降低特异性OVA-IgE水平，联合菌群调节方式效果更好。
5. 各实验组鼻腔灌洗液、肺灌洗液及血清中IL-10、IL-6含量如图5所示。
白介10（IL-10）水平：鼻腔灌洗液中，与M组比，Me组、MePCE组显著上升（p<0.05,p<0.01）；肺灌洗液中，与M组比，Me组有上升趋势、MePCE组显著上升（p<0.05）；血清中，与M组比，Me组、MePCE组显著上升（p<0.05,p<0.05）。
白介6（IL-6）水平：鼻腔灌洗液中，与M组比，Me组有下降趋势，MePCE组显著下降（p<0.05）；肺灌洗液、血清中，与M组比，Me组、MePCE组均有下降趋势。
从图5可以看出，本发明实施例表皮葡萄球菌的调节可以改善幼鼠免疫状态，联合菌群调节方式效果更好。

Claims (1)

1.一种可调节免疫耐受发育延缓变应性进程的菌株，其特征在于：所述菌株为表皮葡萄球菌。
CN201711430811.5A 2017-12-26 2017-12-26 可调节免疫耐受发育延缓变应性进程的菌株 Pending CN109957528A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201711430811.5A CN109957528A (zh) 2017-12-26 2017-12-26 可调节免疫耐受发育延缓变应性进程的菌株

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201711430811.5A CN109957528A (zh) 2017-12-26 2017-12-26 可调节免疫耐受发育延缓变应性进程的菌株

Publications (1)

Publication Number Publication Date
CN109957528A true CN109957528A (zh) 2019-07-02

Family

ID=67021952

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201711430811.5A Pending CN109957528A (zh) 2017-12-26 2017-12-26 可调节免疫耐受发育延缓变应性进程的菌株

Country Status (1)

Country Link
CN (1) CN109957528A (zh)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104274666A (zh) * 2014-10-11 2015-01-14 中山百鸥医药科技有限公司 用于治疗妇科疾病的泡腾片
US20160279177A1 (en) * 2011-10-07 2016-09-29 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160279177A1 (en) * 2011-10-07 2016-09-29 4D Pharma Research Limited Bacterium for use as a probiotic for nutritional and medical applications
CN104274666A (zh) * 2014-10-11 2015-01-14 中山百鸥医药科技有限公司 用于治疗妇科疾病的泡腾片

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
张瑾等: "表皮葡萄球菌对大鼠变应原敏感性的影响", 《中国微生态学杂志》 *

Similar Documents

Publication Publication Date Title
Kim et al. Bifidobacterium longum IM55 and Lactobacillus plantarum IM76 alleviate allergic rhinitis in mice by restoring Th2/Treg imbalance and gut microbiota disturbance
Ochoa-Reparaz et al. A polysaccharide from the human commensal Bacteroides fragilis protects against CNS demyelinating disease
Fu et al. Effect of 3 lactobacilli on immunoregulation and intestinal microbiota in a β-lactoglobulin–induced allergic mouse model
CN104039171B (zh) 包含特定瑞士乳杆菌菌株并且降低食物过敏和/或呼吸道变态反应症状的组合物
Zhang et al. The effects of delivery mode on the gut microbiota and health: state of art
CN104435000A (zh) 乳酸菌对支气管哮喘治疗中的应用
Shin et al. A multistrain probiotic formulation attenuates skin symptoms of atopic dermatitis in a mouse model through the generation of CD4+ Foxp3+ T cells
Ren et al. Immunomodulatory effect of Bifidobacterium breve on experimental allergic rhinitis in BALB/c mice
JP7055520B2 (ja) アッカーマンシア・ムシニフィラｅｂ－ａｍｄｋ２７菌株およびその使用
CA2700922C (en) .beta.-glucan treatment of upper respiratory tract infection symptoms and psychological well-being
Ogita et al. Streptococcus thermophilus ST28 ameliorates colitis in mice partially by suppression of inflammatory Th17 cells
Shimizu et al. Gut as a target for functional food
CN103550258B (zh) 乳酸菌株调节免疫反应的用途
Lei et al. Screening of probiotic Lactobacilli with potential anti-allergic activity based on hyaluronidase inhibition and degranulation of RBL-2H3 cells in vitro
Lee et al. Prebiotics in atopic dermatitis prevention and management
CN103087963B (zh) 一种筛选益生菌的方法
CN109957528A (zh) 可调节免疫耐受发育延缓变应性进程的菌株
Kim et al. Bifidobacterium longum and Lactobacillus plantarum alleviate house dust mite allergen-induced allergic rhinitis by regulating IL-4, IL-5, and IL-10 expression
TWI429444B (zh) 新穎乳酸菌株及其調節免疫反應的用途
Van der Poel et al. Paediatric allergy in review
US20110052553A1 (en) Strain of lactobacillus plantarum lp28 and its use in treating hypersensitivity reactions
Fujiwara et al. 2, 4-Dinitrofluorobenzene-induced contact hypersensitivity response in NC/Nga mice fed fructo-oligosaccharide
WO2011062443A9 (ko) 아토피성 피부염 치료용 젖산균을 포함하는 약학적 조성물 및 상기 균과 함께 배양된 금을 포함한 약학적 조성물
Wang et al. Oral administration of Bacillus coagulans TQ-35 alleviates allergic responses in OVA-sensitive BALB/c mice
Gunec The role of intestinal flora in the immune system

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190702